nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CYP1B1—Progesterone—uterine cancer	0.0925	0.24	CbGbCtD
Dasatinib—CYP1A1—Progesterone—uterine cancer	0.0406	0.105	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—uterine cancer	0.0349	0.0904	CbGbCtD
Dasatinib—CYP1B1—Doxorubicin—uterine cancer	0.0282	0.0732	CbGbCtD
Dasatinib—CYP3A5—Progesterone—uterine cancer	0.0244	0.0632	CbGbCtD
Dasatinib—ABCG2—Carboplatin—uterine cancer	0.0234	0.0608	CbGbCtD
Dasatinib—ABCG2—Etoposide—uterine cancer	0.0197	0.051	CbGbCtD
Dasatinib—CYP1A2—Progesterone—uterine cancer	0.0181	0.047	CbGbCtD
Dasatinib—ABCB1—Progesterone—uterine cancer	0.0159	0.0411	CbGbCtD
Dasatinib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0143	0.0372	CbGbCtD
Dasatinib—ABCG2—Doxorubicin—uterine cancer	0.0134	0.0348	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—uterine cancer	0.0126	0.0326	CbGbCtD
Dasatinib—CYP3A5—Etoposide—uterine cancer	0.0109	0.0283	CbGbCtD
Dasatinib—CYP3A4—Progesterone—uterine cancer	0.0095	0.0246	CbGbCtD
Dasatinib—CYP1A2—Etoposide—uterine cancer	0.00812	0.021	CbGbCtD
Dasatinib—ABCB1—Etoposide—uterine cancer	0.0071	0.0184	CbGbCtD
Dasatinib—ABCB1—Doxorubicin—uterine cancer	0.00484	0.0126	CbGbCtD
Dasatinib—CYP3A4—Etoposide—uterine cancer	0.00425	0.011	CbGbCtD
Dasatinib—CYP3A4—Doxorubicin—uterine cancer	0.0029	0.00752	CbGbCtD
Dasatinib—ERBB3—Podofilox—Etoposide—uterine cancer	0.0008	0.182	CbGdCrCtD
Dasatinib—PKMYT1—Danazol—Progesterone—uterine cancer	0.000569	0.129	CbGdCrCtD
Dasatinib—TESK1—vagina—uterine cancer	0.000442	0.00256	CbGeAlD
Dasatinib—EPHB4—renal system—uterine cancer	0.000438	0.00253	CbGeAlD
Dasatinib—MAP3K2—uterus—uterine cancer	0.000438	0.00253	CbGeAlD
Dasatinib—EPHA2—decidua—uterine cancer	0.000438	0.00253	CbGeAlD
Dasatinib—STK36—female gonad—uterine cancer	0.000438	0.00253	CbGeAlD
Dasatinib—EPHB3—female gonad—uterine cancer	0.000438	0.00253	CbGeAlD
Dasatinib—FYN—decidua—uterine cancer	0.000437	0.00253	CbGeAlD
Dasatinib—BMX—lymph node—uterine cancer	0.000437	0.00252	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—uterine cancer	0.000436	0.00252	CbGeAlD
Dasatinib—JAK2—renal system—uterine cancer	0.000435	0.00252	CbGeAlD
Dasatinib—EPHB3—vagina—uterine cancer	0.000435	0.00251	CbGeAlD
Dasatinib—STK36—vagina—uterine cancer	0.000435	0.00251	CbGeAlD
Dasatinib—BLK—lymph node—uterine cancer	0.000432	0.0025	CbGeAlD
Dasatinib—FGR—mammalian vulva—uterine cancer	0.000431	0.00249	CbGeAlD
Dasatinib—LCK—mammalian vulva—uterine cancer	0.000431	0.00249	CbGeAlD
Dasatinib—FYN—renal system—uterine cancer	0.000429	0.00248	CbGeAlD
Dasatinib—EPHB6—uterine cervix—uterine cancer	0.000429	0.00248	CbGeAlD
Dasatinib—MAP3K3—decidua—uterine cancer	0.000427	0.00247	CbGeAlD
Dasatinib—MAP4K5—decidua—uterine cancer	0.000427	0.00247	CbGeAlD
Dasatinib—EPHB4—endometrium—uterine cancer	0.000424	0.00245	CbGeAlD
Dasatinib—LIMK2—female gonad—uterine cancer	0.000423	0.00245	CbGeAlD
Dasatinib—JAK2—endometrium—uterine cancer	0.000421	0.00243	CbGeAlD
Dasatinib—LIMK2—vagina—uterine cancer	0.00042	0.00243	CbGeAlD
Dasatinib—KIT—myometrium—uterine cancer	0.000417	0.00241	CbGeAlD
Dasatinib—FMO3—mammalian vulva—uterine cancer	0.000416	0.00241	CbGeAlD
Dasatinib—EPHA2—endometrium—uterine cancer	0.000416	0.0024	CbGeAlD
Dasatinib—RIPK2—female reproductive system—uterine cancer	0.000415	0.0024	CbGeAlD
Dasatinib—FYN—endometrium—uterine cancer	0.000415	0.0024	CbGeAlD
Dasatinib—YES1—uterine cervix—uterine cancer	0.000414	0.00239	CbGeAlD
Dasatinib—TXK—lymph node—uterine cancer	0.000413	0.00239	CbGeAlD
Dasatinib—MAPK14—uterus—uterine cancer	0.000412	0.00238	CbGeAlD
Dasatinib—LCK—uterus—uterine cancer	0.00041	0.00237	CbGeAlD
Dasatinib—STK35—female gonad—uterine cancer	0.00041	0.00237	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—uterine cancer	0.00041	0.00237	CbGeAlD
Dasatinib—EPHB6—decidua—uterine cancer	0.000408	0.00236	CbGeAlD
Dasatinib—PDGFRB—myometrium—uterine cancer	0.000408	0.00236	CbGeAlD
Dasatinib—STK35—vagina—uterine cancer	0.000408	0.00236	CbGeAlD
Dasatinib—CSK—female gonad—uterine cancer	0.000407	0.00236	CbGeAlD
Dasatinib—JAK2—mammalian vulva—uterine cancer	0.000407	0.00235	CbGeAlD
Dasatinib—SIK1—female reproductive system—uterine cancer	0.000406	0.00235	CbGeAlD
Dasatinib—MAP3K3—endometrium—uterine cancer	0.000406	0.00235	CbGeAlD
Dasatinib—MAP4K5—endometrium—uterine cancer	0.000406	0.00235	CbGeAlD
Dasatinib—CSK—vagina—uterine cancer	0.000405	0.00234	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—uterine cancer	0.000402	0.00233	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—uterine cancer	0.000402	0.00233	CbGeAlD
Dasatinib—HCK—female gonad—uterine cancer	0.000402	0.00233	CbGeAlD
Dasatinib—SRC—epithelium—uterine cancer	0.000402	0.00232	CbGeAlD
Dasatinib—EPHA4—female reproductive system—uterine cancer	0.000402	0.00232	CbGeAlD
Dasatinib—FYN—mammalian vulva—uterine cancer	0.000401	0.00232	CbGeAlD
Dasatinib—HCK—vagina—uterine cancer	0.0004	0.00231	CbGeAlD
Dasatinib—ABL2—female gonad—uterine cancer	0.0004	0.00231	CbGeAlD
Dasatinib—SRC—uterine cervix—uterine cancer	0.000398	0.0023	CbGeAlD
Dasatinib—ERBB3—female reproductive system—uterine cancer	0.000398	0.0023	CbGeAlD
Dasatinib—ABL2—vagina—uterine cancer	0.000397	0.0023	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—uterine cancer	0.000395	0.00228	CbGeAlD
Dasatinib—YES1—decidua—uterine cancer	0.000395	0.00228	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—uterine cancer	0.000394	0.00228	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—uterine cancer	0.000392	0.00227	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—uterine cancer	0.000392	0.00227	CbGeAlD
Dasatinib—EPHB4—uterus—uterine cancer	0.000391	0.00226	CbGeAlD
Dasatinib—EPHB6—endometrium—uterine cancer	0.000388	0.00224	CbGeAlD
Dasatinib—YES1—renal system—uterine cancer	0.000387	0.00224	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—uterine cancer	0.000387	0.00224	CbGeAlD
Dasatinib—PDGFRA—decidua—uterine cancer	0.000387	0.00224	CbGeAlD
Dasatinib—STAT5B—lymph node—uterine cancer	0.000387	0.00224	CbGeAlD
Dasatinib—CSK—Doxorubicin—Epirubicin—uterine cancer	0.000385	0.0874	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Epirubicin—uterine cancer	0.000385	0.0874	CbGdCrCtD
Dasatinib—FYN—uterus—uterine cancer	0.000382	0.00221	CbGeAlD
Dasatinib—PDGFRA—renal system—uterine cancer	0.00038	0.0022	CbGeAlD
Dasatinib—SRC—decidua—uterine cancer	0.00038	0.00219	CbGeAlD
Dasatinib—RIPK2—female gonad—uterine cancer	0.000378	0.00219	CbGeAlD
Dasatinib—RIPK2—vagina—uterine cancer	0.000376	0.00217	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—uterine cancer	0.000375	0.00217	CbGeAlD
Dasatinib—YES1—endometrium—uterine cancer	0.000375	0.00217	CbGeAlD
Dasatinib—MAP4K5—uterus—uterine cancer	0.000374	0.00216	CbGeAlD
Dasatinib—SRC—renal system—uterine cancer	0.000373	0.00216	CbGeAlD
Dasatinib—MAPK14—female reproductive system—uterine cancer	0.00037	0.00214	CbGeAlD
Dasatinib—SIK1—female gonad—uterine cancer	0.000369	0.00213	CbGeAlD
Dasatinib—FGR—female reproductive system—uterine cancer	0.000369	0.00213	CbGeAlD
Dasatinib—MAP2K5—uterine cervix—uterine cancer	0.000366	0.00212	CbGeAlD
Dasatinib—EPHA4—female gonad—uterine cancer	0.000365	0.00211	CbGeAlD
Dasatinib—ABL1—myometrium—uterine cancer	0.000363	0.0021	CbGeAlD
Dasatinib—EPHA4—vagina—uterine cancer	0.000363	0.0021	CbGeAlD
Dasatinib—YES1—mammalian vulva—uterine cancer	0.000362	0.00209	CbGeAlD
Dasatinib—ERBB3—female gonad—uterine cancer	0.000362	0.00209	CbGeAlD
Dasatinib—MAP3K2—female gonad—uterine cancer	0.000358	0.00207	CbGeAlD
Dasatinib—CSF1R—uterine cervix—uterine cancer	0.000358	0.00207	CbGeAlD
Dasatinib—EPHA3—lymph node—uterine cancer	0.000358	0.00207	CbGeAlD
Dasatinib—CSK—Epirubicin—Doxorubicin—uterine cancer	0.000356	0.0809	CbGdCrCtD
Dasatinib—CSK—Daunorubicin—Doxorubicin—uterine cancer	0.000356	0.0809	CbGdCrCtD
Dasatinib—EPHB4—female reproductive system—uterine cancer	0.000351	0.00203	CbGeAlD
Dasatinib—MAP2K5—decidua—uterine cancer	0.000349	0.00202	CbGeAlD
Dasatinib—JAK2—female reproductive system—uterine cancer	0.000349	0.00202	CbGeAlD
Dasatinib—SIK3—lymph node—uterine cancer	0.000348	0.00201	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—uterine cancer	0.000348	0.00201	CbGeAlD
Dasatinib—YES1—uterus—uterine cancer	0.000345	0.002	CbGeAlD
Dasatinib—EPHA2—female reproductive system—uterine cancer	0.000344	0.00199	CbGeAlD
Dasatinib—FYN—female reproductive system—uterine cancer	0.000344	0.00199	CbGeAlD
Dasatinib—CSF1R—decidua—uterine cancer	0.000341	0.00197	CbGeAlD
Dasatinib—PDGFRA—uterus—uterine cancer	0.000339	0.00196	CbGeAlD
Dasatinib—MAPK14—female gonad—uterine cancer	0.000337	0.00195	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—uterine cancer	0.000336	0.00194	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—uterine cancer	0.000336	0.00194	CbGeAlD
Dasatinib—LCK—female gonad—uterine cancer	0.000336	0.00194	CbGeAlD
Dasatinib—FGR—female gonad—uterine cancer	0.000336	0.00194	CbGeAlD
Dasatinib—MAPK14—vagina—uterine cancer	0.000335	0.00194	CbGeAlD
Dasatinib—FGR—vagina—uterine cancer	0.000334	0.00193	CbGeAlD
Dasatinib—LCK—vagina—uterine cancer	0.000334	0.00193	CbGeAlD
Dasatinib—MAP2K5—endometrium—uterine cancer	0.000331	0.00192	CbGeAlD
Dasatinib—KIT—epithelium—uterine cancer	0.000328	0.00189	CbGeAlD
Dasatinib—KIT—uterine cervix—uterine cancer	0.000325	0.00188	CbGeAlD
Dasatinib—CSF1R—endometrium—uterine cancer	0.000323	0.00187	CbGeAlD
Dasatinib—ZAK—lymph node—uterine cancer	0.000323	0.00187	CbGeAlD
Dasatinib—FMO3—vagina—uterine cancer	0.000322	0.00186	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—uterine cancer	0.000321	0.00185	CbGeAlD
Dasatinib—PDGFRB—epithelium—uterine cancer	0.00032	0.00185	CbGeAlD
Dasatinib—EPHB4—female gonad—uterine cancer	0.000319	0.00185	CbGeAlD
Dasatinib—EPHB4—vagina—uterine cancer	0.000318	0.00184	CbGeAlD
Dasatinib—PDGFRB—uterine cervix—uterine cancer	0.000317	0.00183	CbGeAlD
Dasatinib—JAK2—female gonad—uterine cancer	0.000317	0.00183	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—uterine cancer	0.000316	0.00183	CbGeAlD
Dasatinib—JAK2—vagina—uterine cancer	0.000315	0.00182	CbGeAlD
Dasatinib—EPHA2—female gonad—uterine cancer	0.000313	0.00181	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—uterine cancer	0.000313	0.00181	CbGeAlD
Dasatinib—FYN—female gonad—uterine cancer	0.000313	0.00181	CbGeAlD
Dasatinib—EPHA2—vagina—uterine cancer	0.000311	0.0018	CbGeAlD
Dasatinib—FYN—vagina—uterine cancer	0.000311	0.0018	CbGeAlD
Dasatinib—YES1—female reproductive system—uterine cancer	0.00031	0.00179	CbGeAlD
Dasatinib—BMPR1B—lymph node—uterine cancer	0.00031	0.00179	CbGeAlD
Dasatinib—KIT—decidua—uterine cancer	0.000309	0.00179	CbGeAlD
Dasatinib—BTK—lymph node—uterine cancer	0.000308	0.00178	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—uterine cancer	0.000308	0.00178	CbGeAlD
Dasatinib—MAP4K5—female gonad—uterine cancer	0.000306	0.00177	CbGeAlD
Dasatinib—MAP3K3—female gonad—uterine cancer	0.000306	0.00177	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—uterine cancer	0.000304	0.00176	CbGeAlD
Dasatinib—TNK2—lymph node—uterine cancer	0.000304	0.00176	CbGeAlD
Dasatinib—MAP4K5—vagina—uterine cancer	0.000304	0.00176	CbGeAlD
Dasatinib—MAP3K3—vagina—uterine cancer	0.000304	0.00176	CbGeAlD
Dasatinib—KIT—renal system—uterine cancer	0.000304	0.00176	CbGeAlD
Dasatinib—PDGFRB—decidua—uterine cancer	0.000302	0.00175	CbGeAlD
Dasatinib—SRC—female reproductive system—uterine cancer	0.000299	0.00173	CbGeAlD
Dasatinib—CSF1R—uterus—uterine cancer	0.000298	0.00172	CbGeAlD
Dasatinib—PDGFRB—renal system—uterine cancer	0.000297	0.00172	CbGeAlD
Dasatinib—KIT—endometrium—uterine cancer	0.000294	0.0017	CbGeAlD
Dasatinib—EPHB6—female gonad—uterine cancer	0.000292	0.00169	CbGeAlD
Dasatinib—EPHB6—vagina—uterine cancer	0.00029	0.00168	CbGeAlD
Dasatinib—PDGFRB—endometrium—uterine cancer	0.000287	0.00166	CbGeAlD
Dasatinib—TESK1—lymph node—uterine cancer	0.000286	0.00165	CbGeAlD
Dasatinib—KIT—mammalian vulva—uterine cancer	0.000284	0.00164	CbGeAlD
Dasatinib—ABL1—uterine cervix—uterine cancer	0.000283	0.00163	CbGeAlD
Dasatinib—YES1—female gonad—uterine cancer	0.000282	0.00163	CbGeAlD
Dasatinib—STK36—lymph node—uterine cancer	0.000281	0.00163	CbGeAlD
Dasatinib—EPHB3—lymph node—uterine cancer	0.000281	0.00163	CbGeAlD
Dasatinib—YES1—vagina—uterine cancer	0.000281	0.00162	CbGeAlD
Dasatinib—PDGFRB—mammalian vulva—uterine cancer	0.000278	0.0016	CbGeAlD
Dasatinib—PDGFRA—female gonad—uterine cancer	0.000277	0.0016	CbGeAlD
Dasatinib—PDGFRA—vagina—uterine cancer	0.000275	0.00159	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—uterine cancer	0.000275	0.00159	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—uterine cancer	0.000275	0.00159	CbGeAlD
Dasatinib—LIMK2—lymph node—uterine cancer	0.000272	0.00157	CbGeAlD
Dasatinib—SRC—female gonad—uterine cancer	0.000272	0.00157	CbGeAlD
Dasatinib—KIT—uterus—uterine cancer	0.000271	0.00157	CbGeAlD
Dasatinib—ABL1—decidua—uterine cancer	0.000269	0.00156	CbGeAlD
Dasatinib—ABL1—Daunorubicin—Epirubicin—uterine cancer	0.000269	0.061	CbGdCrCtD
Dasatinib—ABL1—Doxorubicin—Epirubicin—uterine cancer	0.000269	0.061	CbGdCrCtD
Dasatinib—ABL1—Idarubicin—Epirubicin—uterine cancer	0.000269	0.061	CbGdCrCtD
Dasatinib—CSF1R—female reproductive system—uterine cancer	0.000268	0.00155	CbGeAlD
Dasatinib—ABL1—renal system—uterine cancer	0.000265	0.00153	CbGeAlD
Dasatinib—PDGFRB—uterus—uterine cancer	0.000264	0.00153	CbGeAlD
Dasatinib—STK35—lymph node—uterine cancer	0.000264	0.00152	CbGeAlD
Dasatinib—CSK—lymph node—uterine cancer	0.000262	0.00151	CbGeAlD
Dasatinib—HCK—lymph node—uterine cancer	0.000259	0.00149	CbGeAlD
Dasatinib—ABL2—lymph node—uterine cancer	0.000257	0.00149	CbGeAlD
Dasatinib—ABL1—endometrium—uterine cancer	0.000256	0.00148	CbGeAlD
Dasatinib—MAP2K5—female gonad—uterine cancer	0.00025	0.00144	CbGeAlD
Dasatinib—ABL1—Idarubicin—Doxorubicin—uterine cancer	0.000249	0.0565	CbGdCrCtD
Dasatinib—ABL1—Daunorubicin—Doxorubicin—uterine cancer	0.000249	0.0565	CbGdCrCtD
Dasatinib—ABL1—Epirubicin—Doxorubicin—uterine cancer	0.000249	0.0565	CbGdCrCtD
Dasatinib—MAP2K5—vagina—uterine cancer	0.000248	0.00144	CbGeAlD
Dasatinib—ABL1—mammalian vulva—uterine cancer	0.000247	0.00143	CbGeAlD
Dasatinib—CSF1R—female gonad—uterine cancer	0.000244	0.00141	CbGeAlD
Dasatinib—KIT—female reproductive system—uterine cancer	0.000243	0.00141	CbGeAlD
Dasatinib—RIPK2—lymph node—uterine cancer	0.000243	0.00141	CbGeAlD
Dasatinib—CSF1R—vagina—uterine cancer	0.000242	0.0014	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—uterine cancer	0.000238	0.00137	CbGeAlD
Dasatinib—SIK1—lymph node—uterine cancer	0.000237	0.00137	CbGeAlD
Dasatinib—ABL1—uterus—uterine cancer	0.000236	0.00136	CbGeAlD
Dasatinib—EPHA4—lymph node—uterine cancer	0.000235	0.00136	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—uterine cancer	0.000233	0.00135	CbGeAlD
Dasatinib—ERBB3—lymph node—uterine cancer	0.000233	0.00135	CbGeAlD
Dasatinib—MAP3K2—lymph node—uterine cancer	0.00023	0.00133	CbGeAlD
Dasatinib—ABCG2—myometrium—uterine cancer	0.000229	0.00132	CbGeAlD
Dasatinib—CYP1B1—decidua—uterine cancer	0.000228	0.00132	CbGeAlD
Dasatinib—CYP1B1—renal system—uterine cancer	0.000224	0.0013	CbGeAlD
Dasatinib—KIT—female gonad—uterine cancer	0.000221	0.00128	CbGeAlD
Dasatinib—KIT—vagina—uterine cancer	0.00022	0.00127	CbGeAlD
Dasatinib—MAPK14—lymph node—uterine cancer	0.000217	0.00125	CbGeAlD
Dasatinib—PDGFRB—female gonad—uterine cancer	0.000216	0.00125	CbGeAlD
Dasatinib—FGR—lymph node—uterine cancer	0.000216	0.00125	CbGeAlD
Dasatinib—LCK—lymph node—uterine cancer	0.000216	0.00125	CbGeAlD
Dasatinib—PDGFRB—vagina—uterine cancer	0.000215	0.00124	CbGeAlD
Dasatinib—ABL1—female reproductive system—uterine cancer	0.000212	0.00122	CbGeAlD
Dasatinib—FMO3—lymph node—uterine cancer	0.000208	0.0012	CbGeAlD
Dasatinib—EPHB4—lymph node—uterine cancer	0.000205	0.00119	CbGeAlD
Dasatinib—JAK2—lymph node—uterine cancer	0.000204	0.00118	CbGeAlD
Dasatinib—EPHA2—lymph node—uterine cancer	0.000201	0.00116	CbGeAlD
Dasatinib—FYN—lymph node—uterine cancer	0.000201	0.00116	CbGeAlD
Dasatinib—CYP1B1—uterus—uterine cancer	0.0002	0.00115	CbGeAlD
Dasatinib—MAP3K3—lymph node—uterine cancer	0.000197	0.00114	CbGeAlD
Dasatinib—MAP4K5—lymph node—uterine cancer	0.000197	0.00114	CbGeAlD
Dasatinib—ABL1—female gonad—uterine cancer	0.000193	0.00111	CbGeAlD
Dasatinib—ABL1—vagina—uterine cancer	0.000192	0.00111	CbGeAlD
Dasatinib—EPHB6—lymph node—uterine cancer	0.000188	0.00109	CbGeAlD
Dasatinib—YES1—lymph node—uterine cancer	0.000182	0.00105	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—uterine cancer	0.000179	0.00104	CbGeAlD
Dasatinib—ABCG2—uterine cervix—uterine cancer	0.000178	0.00103	CbGeAlD
Dasatinib—PDGFRA—lymph node—uterine cancer	0.000178	0.00103	CbGeAlD
Dasatinib—SRC—lymph node—uterine cancer	0.000175	0.00101	CbGeAlD
Dasatinib—CYP1A1—epithelium—uterine cancer	0.000171	0.000987	CbGeAlD
Dasatinib—ABCG2—decidua—uterine cancer	0.00017	0.000982	CbGeAlD
Dasatinib—CYP1A1—uterine cervix—uterine cancer	0.000169	0.000979	CbGeAlD
Dasatinib—CYP3A5—uterine cervix—uterine cancer	0.000166	0.000957	CbGeAlD
Dasatinib—CYP1B1—female gonad—uterine cancer	0.000163	0.000944	CbGeAlD
Dasatinib—ABCG2—endometrium—uterine cancer	0.000161	0.000932	CbGeAlD
Dasatinib—MAP2K5—lymph node—uterine cancer	0.000161	0.000929	CbGeAlD
Dasatinib—CYP1A2—renal system—uterine cancer	0.000161	0.000928	CbGeAlD
Dasatinib—CYP1A1—renal system—uterine cancer	0.000158	0.000916	CbGeAlD
Dasatinib—CSF1R—lymph node—uterine cancer	0.000157	0.000906	CbGeAlD
Dasatinib—ABCG2—mammalian vulva—uterine cancer	0.000156	0.000902	CbGeAlD
Dasatinib—CYP3A5—renal system—uterine cancer	0.000155	0.000895	CbGeAlD
Dasatinib—ABCG2—uterus—uterine cancer	0.000149	0.000859	CbGeAlD
Dasatinib—CYP1A1—mammalian vulva—uterine cancer	0.000148	0.000856	CbGeAlD
Dasatinib—KIT—lymph node—uterine cancer	0.000142	0.000823	CbGeAlD
Dasatinib—CYP1A1—uterus—uterine cancer	0.000141	0.000816	CbGeAlD
Dasatinib—PDGFRB—lymph node—uterine cancer	0.000139	0.000804	CbGeAlD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000127	0.00063	CcSEcCtD
Dasatinib—CYP1A1—female reproductive system—uterine cancer	0.000127	0.000733	CbGeAlD
Dasatinib—Discomfort—Etoposide—uterine cancer	0.000127	0.000626	CcSEcCtD
Dasatinib—Breast disorder—Epirubicin—uterine cancer	0.000127	0.000626	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000126	0.000624	CcSEcCtD
Dasatinib—Face oedema—Doxorubicin—uterine cancer	0.000125	0.000619	CcSEcCtD
Dasatinib—Hypersensitivity—Dactinomycin—uterine cancer	0.000125	0.000619	CcSEcCtD
Dasatinib—Gastritis—Epirubicin—uterine cancer	0.000124	0.000613	CcSEcCtD
Dasatinib—Confusional state—Etoposide—uterine cancer	0.000124	0.000613	CcSEcCtD
Dasatinib—ABL1—lymph node—uterine cancer	0.000124	0.000717	CbGeAlD
Dasatinib—Muscular weakness—Epirubicin—uterine cancer	0.000124	0.000611	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000124	0.000611	CcSEcCtD
Dasatinib—Infection—Etoposide—uterine cancer	0.000122	0.000604	CcSEcCtD
Dasatinib—Abdominal distension—Epirubicin—uterine cancer	0.000122	0.000603	CcSEcCtD
Dasatinib—Asthenia—Dactinomycin—uterine cancer	0.000122	0.000603	CcSEcCtD
Dasatinib—ABCG2—female gonad—uterine cancer	0.000122	0.000703	CbGeAlD
Dasatinib—Blood creatinine increased—Doxorubicin—uterine cancer	0.000122	0.000601	CcSEcCtD
Dasatinib—Asthma—Epirubicin—uterine cancer	0.000121	0.000599	CcSEcCtD
Dasatinib—Dysphagia—Epirubicin—uterine cancer	0.000121	0.000599	CcSEcCtD
Dasatinib—ABCG2—vagina—uterine cancer	0.000121	0.000699	CbGeAlD
Dasatinib—Thrombocytopenia—Etoposide—uterine cancer	0.00012	0.000595	CcSEcCtD
Dasatinib—Tachycardia—Etoposide—uterine cancer	0.00012	0.000593	CcSEcCtD
Dasatinib—Skin disorder—Etoposide—uterine cancer	0.000119	0.00059	CcSEcCtD
Dasatinib—Dry skin—Doxorubicin—uterine cancer	0.000119	0.000588	CcSEcCtD
Dasatinib—Hyperhidrosis—Etoposide—uterine cancer	0.000119	0.000588	CcSEcCtD
Dasatinib—Pancreatitis—Epirubicin—uterine cancer	0.000119	0.000587	CcSEcCtD
Dasatinib—Hypokalaemia—Doxorubicin—uterine cancer	0.000118	0.000584	CcSEcCtD
Dasatinib—Angina pectoris—Epirubicin—uterine cancer	0.000118	0.000584	CcSEcCtD
Dasatinib—Breast disorder—Doxorubicin—uterine cancer	0.000117	0.00058	CcSEcCtD
Dasatinib—Anorexia—Etoposide—uterine cancer	0.000117	0.000579	CcSEcCtD
Dasatinib—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000117	0.000578	CcSEcCtD
Dasatinib—Diarrhoea—Dactinomycin—uterine cancer	0.000116	0.000575	CcSEcCtD
Dasatinib—CYP3A4—renal system—uterine cancer	0.000116	0.000672	CbGeAlD
Dasatinib—CYP1A1—female gonad—uterine cancer	0.000115	0.000667	CbGeAlD
Dasatinib—Pancytopenia—Epirubicin—uterine cancer	0.000115	0.000569	CcSEcCtD
Dasatinib—Hypotension—Etoposide—uterine cancer	0.000115	0.000568	CcSEcCtD
Dasatinib—Gastritis—Doxorubicin—uterine cancer	0.000115	0.000568	CcSEcCtD
Dasatinib—CYP1A1—vagina—uterine cancer	0.000115	0.000663	CbGeAlD
Dasatinib—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000114	0.000566	CcSEcCtD
Dasatinib—Muscular weakness—Doxorubicin—uterine cancer	0.000114	0.000566	CcSEcCtD
Dasatinib—Neutropenia—Epirubicin—uterine cancer	0.000113	0.00056	CcSEcCtD
Dasatinib—ABCB1—myometrium—uterine cancer	0.000113	0.000653	CbGeAlD
Dasatinib—Abdominal distension—Doxorubicin—uterine cancer	0.000113	0.000558	CcSEcCtD
Dasatinib—CYP3A5—female gonad—uterine cancer	0.000113	0.000652	CbGeAlD
Dasatinib—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000113	0.000557	CcSEcCtD
Dasatinib—CYP3A5—vagina—uterine cancer	0.000112	0.000648	CbGeAlD
Dasatinib—Asthma—Doxorubicin—uterine cancer	0.000112	0.000554	CcSEcCtD
Dasatinib—Dysphagia—Doxorubicin—uterine cancer	0.000112	0.000554	CcSEcCtD
Dasatinib—Pollakiuria—Epirubicin—uterine cancer	0.000112	0.000553	CcSEcCtD
Dasatinib—Photosensitivity reaction—Epirubicin—uterine cancer	0.000111	0.000547	CcSEcCtD
Dasatinib—Weight increased—Epirubicin—uterine cancer	0.00011	0.000545	CcSEcCtD
Dasatinib—Pancreatitis—Doxorubicin—uterine cancer	0.00011	0.000544	CcSEcCtD
Dasatinib—Weight decreased—Epirubicin—uterine cancer	0.00011	0.000542	CcSEcCtD
Dasatinib—Dyspnoea—Etoposide—uterine cancer	0.00011	0.000542	CcSEcCtD
Dasatinib—Somnolence—Etoposide—uterine cancer	0.000109	0.00054	CcSEcCtD
Dasatinib—Angina pectoris—Doxorubicin—uterine cancer	0.000109	0.00054	CcSEcCtD
Dasatinib—Pneumonia—Epirubicin—uterine cancer	0.000109	0.000537	CcSEcCtD
Dasatinib—Infestation NOS—Epirubicin—uterine cancer	0.000108	0.000534	CcSEcCtD
Dasatinib—Infestation—Epirubicin—uterine cancer	0.000108	0.000534	CcSEcCtD
Dasatinib—Vomiting—Dactinomycin—uterine cancer	0.000108	0.000534	CcSEcCtD
Dasatinib—Rash—Dactinomycin—uterine cancer	0.000107	0.00053	CcSEcCtD
Dasatinib—Decreased appetite—Etoposide—uterine cancer	0.000107	0.000528	CcSEcCtD
Dasatinib—Pancytopenia—Doxorubicin—uterine cancer	0.000106	0.000526	CcSEcCtD
Dasatinib—Renal failure—Epirubicin—uterine cancer	0.000106	0.000525	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Etoposide—uterine cancer	0.000106	0.000525	CcSEcCtD
Dasatinib—Fatigue—Etoposide—uterine cancer	0.000106	0.000524	CcSEcCtD
Dasatinib—Neuropathy peripheral—Epirubicin—uterine cancer	0.000106	0.000524	CcSEcCtD
Dasatinib—Stomatitis—Epirubicin—uterine cancer	0.000105	0.000521	CcSEcCtD
Dasatinib—Pain—Etoposide—uterine cancer	0.000105	0.00052	CcSEcCtD
Dasatinib—Constipation—Etoposide—uterine cancer	0.000105	0.00052	CcSEcCtD
Dasatinib—Conjunctivitis—Epirubicin—uterine cancer	0.000105	0.000519	CcSEcCtD
Dasatinib—CYP1B1—lymph node—uterine cancer	0.000105	0.000607	CbGeAlD
Dasatinib—Neutropenia—Doxorubicin—uterine cancer	0.000105	0.000518	CcSEcCtD
Dasatinib—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000104	0.000515	CcSEcCtD
Dasatinib—Pollakiuria—Doxorubicin—uterine cancer	0.000104	0.000512	CcSEcCtD
Dasatinib—Haematuria—Epirubicin—uterine cancer	0.000103	0.000509	CcSEcCtD
Dasatinib—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000102	0.000506	CcSEcCtD
Dasatinib—Hepatobiliary disease—Epirubicin—uterine cancer	0.000102	0.000505	CcSEcCtD
Dasatinib—Weight increased—Doxorubicin—uterine cancer	0.000102	0.000505	CcSEcCtD
Dasatinib—Epistaxis—Epirubicin—uterine cancer	0.000102	0.000504	CcSEcCtD
Dasatinib—Weight decreased—Doxorubicin—uterine cancer	0.000101	0.000502	CcSEcCtD
Dasatinib—Feeling abnormal—Etoposide—uterine cancer	0.000101	0.000501	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—uterine cancer	0.000101	0.000499	CcSEcCtD
Dasatinib—Pneumonia—Doxorubicin—uterine cancer	0.000101	0.000497	CcSEcCtD
Dasatinib—Gastrointestinal pain—Etoposide—uterine cancer	0.000101	0.000497	CcSEcCtD
Dasatinib—Infestation—Doxorubicin—uterine cancer	0.0001	0.000494	CcSEcCtD
Dasatinib—Infestation NOS—Doxorubicin—uterine cancer	0.0001	0.000494	CcSEcCtD
Dasatinib—Renal failure—Doxorubicin—uterine cancer	9.83e-05	0.000486	CcSEcCtD
Dasatinib—Neuropathy peripheral—Doxorubicin—uterine cancer	9.8e-05	0.000485	CcSEcCtD
Dasatinib—Urticaria—Etoposide—uterine cancer	9.77e-05	0.000483	CcSEcCtD
Dasatinib—Haemoglobin—Epirubicin—uterine cancer	9.75e-05	0.000482	CcSEcCtD
Dasatinib—Stomatitis—Doxorubicin—uterine cancer	9.75e-05	0.000482	CcSEcCtD
Dasatinib—Abdominal pain—Etoposide—uterine cancer	9.72e-05	0.00048	CcSEcCtD
Dasatinib—Body temperature increased—Etoposide—uterine cancer	9.72e-05	0.00048	CcSEcCtD
Dasatinib—Conjunctivitis—Doxorubicin—uterine cancer	9.72e-05	0.00048	CcSEcCtD
Dasatinib—Hepatitis—Epirubicin—uterine cancer	9.7e-05	0.00048	CcSEcCtD
Dasatinib—Haemorrhage—Epirubicin—uterine cancer	9.7e-05	0.00048	CcSEcCtD
Dasatinib—Urinary tract disorder—Epirubicin—uterine cancer	9.58e-05	0.000474	CcSEcCtD
Dasatinib—Oedema peripheral—Epirubicin—uterine cancer	9.56e-05	0.000472	CcSEcCtD
Dasatinib—Haematuria—Doxorubicin—uterine cancer	9.53e-05	0.000471	CcSEcCtD
Dasatinib—Connective tissue disorder—Epirubicin—uterine cancer	9.53e-05	0.000471	CcSEcCtD
Dasatinib—Urethral disorder—Epirubicin—uterine cancer	9.51e-05	0.00047	CcSEcCtD
Dasatinib—Hepatobiliary disease—Doxorubicin—uterine cancer	9.46e-05	0.000467	CcSEcCtD
Dasatinib—Epistaxis—Doxorubicin—uterine cancer	9.43e-05	0.000466	CcSEcCtD
Dasatinib—Visual impairment—Epirubicin—uterine cancer	9.35e-05	0.000462	CcSEcCtD
Dasatinib—CYP3A4—female reproductive system—uterine cancer	9.31e-05	0.000538	CbGeAlD
Dasatinib—Erythema multiforme—Epirubicin—uterine cancer	9.17e-05	0.000453	CcSEcCtD
Dasatinib—Eye disorder—Epirubicin—uterine cancer	9.06e-05	0.000448	CcSEcCtD
Dasatinib—Hypersensitivity—Etoposide—uterine cancer	9.06e-05	0.000448	CcSEcCtD
Dasatinib—Tinnitus—Epirubicin—uterine cancer	9.04e-05	0.000447	CcSEcCtD
Dasatinib—Haemoglobin—Doxorubicin—uterine cancer	9.02e-05	0.000446	CcSEcCtD
Dasatinib—Cardiac disorder—Epirubicin—uterine cancer	9e-05	0.000445	CcSEcCtD
Dasatinib—Flushing—Epirubicin—uterine cancer	9e-05	0.000445	CcSEcCtD
Dasatinib—Hepatitis—Doxorubicin—uterine cancer	8.98e-05	0.000444	CcSEcCtD
Dasatinib—Haemorrhage—Doxorubicin—uterine cancer	8.98e-05	0.000444	CcSEcCtD
Dasatinib—ABCB1—epithelium—uterine cancer	8.87e-05	0.000513	CbGeAlD
Dasatinib—Urinary tract disorder—Doxorubicin—uterine cancer	8.86e-05	0.000438	CcSEcCtD
Dasatinib—Oedema peripheral—Doxorubicin—uterine cancer	8.84e-05	0.000437	CcSEcCtD
Dasatinib—Asthenia—Etoposide—uterine cancer	8.82e-05	0.000436	CcSEcCtD
Dasatinib—Connective tissue disorder—Doxorubicin—uterine cancer	8.82e-05	0.000436	CcSEcCtD
Dasatinib—Angiopathy—Epirubicin—uterine cancer	8.8e-05	0.000435	CcSEcCtD
Dasatinib—Urethral disorder—Doxorubicin—uterine cancer	8.8e-05	0.000435	CcSEcCtD
Dasatinib—ABCB1—uterine cervix—uterine cancer	8.79e-05	0.000508	CbGeAlD
Dasatinib—Immune system disorder—Epirubicin—uterine cancer	8.76e-05	0.000433	CcSEcCtD
Dasatinib—Mediastinal disorder—Epirubicin—uterine cancer	8.74e-05	0.000432	CcSEcCtD
Dasatinib—Chills—Epirubicin—uterine cancer	8.7e-05	0.00043	CcSEcCtD
Dasatinib—Pruritus—Etoposide—uterine cancer	8.7e-05	0.00043	CcSEcCtD
Dasatinib—Arrhythmia—Epirubicin—uterine cancer	8.67e-05	0.000428	CcSEcCtD
Dasatinib—Visual impairment—Doxorubicin—uterine cancer	8.65e-05	0.000428	CcSEcCtD
Dasatinib—Alopecia—Epirubicin—uterine cancer	8.57e-05	0.000424	CcSEcCtD
Dasatinib—Mental disorder—Epirubicin—uterine cancer	8.5e-05	0.00042	CcSEcCtD
Dasatinib—Erythema multiforme—Doxorubicin—uterine cancer	8.49e-05	0.00042	CcSEcCtD
Dasatinib—Erythema—Epirubicin—uterine cancer	8.44e-05	0.000417	CcSEcCtD
Dasatinib—Malnutrition—Epirubicin—uterine cancer	8.44e-05	0.000417	CcSEcCtD
Dasatinib—Diarrhoea—Etoposide—uterine cancer	8.41e-05	0.000416	CcSEcCtD
Dasatinib—Eye disorder—Doxorubicin—uterine cancer	8.39e-05	0.000415	CcSEcCtD
Dasatinib—ABCB1—decidua—uterine cancer	8.38e-05	0.000484	CbGeAlD
Dasatinib—Tinnitus—Doxorubicin—uterine cancer	8.37e-05	0.000414	CcSEcCtD
Dasatinib—Cardiac disorder—Doxorubicin—uterine cancer	8.33e-05	0.000412	CcSEcCtD
Dasatinib—Flushing—Doxorubicin—uterine cancer	8.33e-05	0.000412	CcSEcCtD
Dasatinib—Dysgeusia—Epirubicin—uterine cancer	8.27e-05	0.000409	CcSEcCtD
Dasatinib—ABCB1—renal system—uterine cancer	8.22e-05	0.000476	CbGeAlD
Dasatinib—Angiopathy—Doxorubicin—uterine cancer	8.14e-05	0.000403	CcSEcCtD
Dasatinib—Dizziness—Etoposide—uterine cancer	8.13e-05	0.000402	CcSEcCtD
Dasatinib—Muscle spasms—Epirubicin—uterine cancer	8.12e-05	0.000401	CcSEcCtD
Dasatinib—Immune system disorder—Doxorubicin—uterine cancer	8.11e-05	0.000401	CcSEcCtD
Dasatinib—Mediastinal disorder—Doxorubicin—uterine cancer	8.09e-05	0.0004	CcSEcCtD
Dasatinib—Chills—Doxorubicin—uterine cancer	8.05e-05	0.000398	CcSEcCtD
Dasatinib—Arrhythmia—Doxorubicin—uterine cancer	8.02e-05	0.000396	CcSEcCtD
Dasatinib—Vision blurred—Epirubicin—uterine cancer	7.96e-05	0.000393	CcSEcCtD
Dasatinib—ABCB1—endometrium—uterine cancer	7.95e-05	0.00046	CbGeAlD
Dasatinib—Alopecia—Doxorubicin—uterine cancer	7.93e-05	0.000392	CcSEcCtD
Dasatinib—Mental disorder—Doxorubicin—uterine cancer	7.86e-05	0.000389	CcSEcCtD
Dasatinib—Ill-defined disorder—Epirubicin—uterine cancer	7.83e-05	0.000387	CcSEcCtD
Dasatinib—Vomiting—Etoposide—uterine cancer	7.82e-05	0.000386	CcSEcCtD
Dasatinib—ABCG2—lymph node—uterine cancer	7.81e-05	0.000452	CbGeAlD
Dasatinib—Erythema—Doxorubicin—uterine cancer	7.81e-05	0.000386	CcSEcCtD
Dasatinib—Malnutrition—Doxorubicin—uterine cancer	7.81e-05	0.000386	CcSEcCtD
Dasatinib—Anaemia—Epirubicin—uterine cancer	7.8e-05	0.000386	CcSEcCtD
Dasatinib—Rash—Etoposide—uterine cancer	7.75e-05	0.000383	CcSEcCtD
Dasatinib—Dermatitis—Etoposide—uterine cancer	7.74e-05	0.000383	CcSEcCtD
Dasatinib—Headache—Etoposide—uterine cancer	7.7e-05	0.000381	CcSEcCtD
Dasatinib—ABCB1—mammalian vulva—uterine cancer	7.69e-05	0.000445	CbGeAlD
Dasatinib—Dysgeusia—Doxorubicin—uterine cancer	7.65e-05	0.000378	CcSEcCtD
Dasatinib—Malaise—Epirubicin—uterine cancer	7.61e-05	0.000376	CcSEcCtD
Dasatinib—Vertigo—Epirubicin—uterine cancer	7.59e-05	0.000375	CcSEcCtD
Dasatinib—Syncope—Epirubicin—uterine cancer	7.57e-05	0.000374	CcSEcCtD
Dasatinib—Muscle spasms—Doxorubicin—uterine cancer	7.51e-05	0.000371	CcSEcCtD
Dasatinib—Palpitations—Epirubicin—uterine cancer	7.46e-05	0.000369	CcSEcCtD
Dasatinib—Loss of consciousness—Epirubicin—uterine cancer	7.42e-05	0.000367	CcSEcCtD
Dasatinib—CYP1A1—lymph node—uterine cancer	7.42e-05	0.000429	CbGeAlD
Dasatinib—Cough—Epirubicin—uterine cancer	7.37e-05	0.000364	CcSEcCtD
Dasatinib—Vision blurred—Doxorubicin—uterine cancer	7.36e-05	0.000364	CcSEcCtD
Dasatinib—ABCB1—uterus—uterine cancer	7.33e-05	0.000424	CbGeAlD
Dasatinib—Convulsion—Epirubicin—uterine cancer	7.32e-05	0.000362	CcSEcCtD
Dasatinib—Nausea—Etoposide—uterine cancer	7.3e-05	0.000361	CcSEcCtD
Dasatinib—Hypertension—Epirubicin—uterine cancer	7.29e-05	0.00036	CcSEcCtD
Dasatinib—Ill-defined disorder—Doxorubicin—uterine cancer	7.25e-05	0.000358	CcSEcCtD
Dasatinib—Anaemia—Doxorubicin—uterine cancer	7.22e-05	0.000357	CcSEcCtD
Dasatinib—Chest pain—Epirubicin—uterine cancer	7.19e-05	0.000355	CcSEcCtD
Dasatinib—Myalgia—Epirubicin—uterine cancer	7.19e-05	0.000355	CcSEcCtD
Dasatinib—Arthralgia—Epirubicin—uterine cancer	7.19e-05	0.000355	CcSEcCtD
Dasatinib—Anxiety—Epirubicin—uterine cancer	7.16e-05	0.000354	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	7.14e-05	0.000353	CcSEcCtD
Dasatinib—Discomfort—Epirubicin—uterine cancer	7.1e-05	0.000351	CcSEcCtD
Dasatinib—Malaise—Doxorubicin—uterine cancer	7.05e-05	0.000348	CcSEcCtD
Dasatinib—Vertigo—Doxorubicin—uterine cancer	7.02e-05	0.000347	CcSEcCtD
Dasatinib—Syncope—Doxorubicin—uterine cancer	7.01e-05	0.000346	CcSEcCtD
Dasatinib—Confusional state—Epirubicin—uterine cancer	6.95e-05	0.000344	CcSEcCtD
Dasatinib—Palpitations—Doxorubicin—uterine cancer	6.9e-05	0.000341	CcSEcCtD
Dasatinib—Oedema—Epirubicin—uterine cancer	6.89e-05	0.000341	CcSEcCtD
Dasatinib—Loss of consciousness—Doxorubicin—uterine cancer	6.87e-05	0.00034	CcSEcCtD
Dasatinib—Infection—Epirubicin—uterine cancer	6.85e-05	0.000338	CcSEcCtD
Dasatinib—Cough—Doxorubicin—uterine cancer	6.82e-05	0.000337	CcSEcCtD
Dasatinib—Shock—Epirubicin—uterine cancer	6.78e-05	0.000335	CcSEcCtD
Dasatinib—Convulsion—Doxorubicin—uterine cancer	6.77e-05	0.000335	CcSEcCtD
Dasatinib—Nervous system disorder—Epirubicin—uterine cancer	6.76e-05	0.000334	CcSEcCtD
Dasatinib—Thrombocytopenia—Epirubicin—uterine cancer	6.75e-05	0.000334	CcSEcCtD
Dasatinib—Hypertension—Doxorubicin—uterine cancer	6.75e-05	0.000333	CcSEcCtD
Dasatinib—Tachycardia—Epirubicin—uterine cancer	6.73e-05	0.000333	CcSEcCtD
Dasatinib—Skin disorder—Epirubicin—uterine cancer	6.69e-05	0.000331	CcSEcCtD
Dasatinib—Hyperhidrosis—Epirubicin—uterine cancer	6.66e-05	0.000329	CcSEcCtD
Dasatinib—Chest pain—Doxorubicin—uterine cancer	6.65e-05	0.000329	CcSEcCtD
Dasatinib—Myalgia—Doxorubicin—uterine cancer	6.65e-05	0.000329	CcSEcCtD
Dasatinib—Arthralgia—Doxorubicin—uterine cancer	6.65e-05	0.000329	CcSEcCtD
Dasatinib—Anxiety—Doxorubicin—uterine cancer	6.63e-05	0.000328	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	6.61e-05	0.000327	CcSEcCtD
Dasatinib—ABCB1—female reproductive system—uterine cancer	6.59e-05	0.000381	CbGeAlD
Dasatinib—Discomfort—Doxorubicin—uterine cancer	6.57e-05	0.000325	CcSEcCtD
Dasatinib—Anorexia—Epirubicin—uterine cancer	6.57e-05	0.000325	CcSEcCtD
Dasatinib—Hypotension—Epirubicin—uterine cancer	6.44e-05	0.000318	CcSEcCtD
Dasatinib—Confusional state—Doxorubicin—uterine cancer	6.43e-05	0.000318	CcSEcCtD
Dasatinib—Oedema—Doxorubicin—uterine cancer	6.38e-05	0.000315	CcSEcCtD
Dasatinib—Infection—Doxorubicin—uterine cancer	6.33e-05	0.000313	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Epirubicin—uterine cancer	6.28e-05	0.00031	CcSEcCtD
Dasatinib—Shock—Doxorubicin—uterine cancer	6.27e-05	0.00031	CcSEcCtD
Dasatinib—Nervous system disorder—Doxorubicin—uterine cancer	6.25e-05	0.000309	CcSEcCtD
Dasatinib—Thrombocytopenia—Doxorubicin—uterine cancer	6.24e-05	0.000309	CcSEcCtD
Dasatinib—Insomnia—Epirubicin—uterine cancer	6.23e-05	0.000308	CcSEcCtD
Dasatinib—Tachycardia—Doxorubicin—uterine cancer	6.22e-05	0.000308	CcSEcCtD
Dasatinib—Skin disorder—Doxorubicin—uterine cancer	6.19e-05	0.000306	CcSEcCtD
Dasatinib—Hyperhidrosis—Doxorubicin—uterine cancer	6.16e-05	0.000305	CcSEcCtD
Dasatinib—Dyspnoea—Epirubicin—uterine cancer	6.14e-05	0.000304	CcSEcCtD
Dasatinib—Somnolence—Epirubicin—uterine cancer	6.13e-05	0.000303	CcSEcCtD
Dasatinib—Anorexia—Doxorubicin—uterine cancer	6.08e-05	0.0003	CcSEcCtD
Dasatinib—Dyspepsia—Epirubicin—uterine cancer	6.07e-05	0.0003	CcSEcCtD
Dasatinib—ABCB1—female gonad—uterine cancer	5.99e-05	0.000347	CbGeAlD
Dasatinib—Decreased appetite—Epirubicin—uterine cancer	5.99e-05	0.000296	CcSEcCtD
Dasatinib—Hypotension—Doxorubicin—uterine cancer	5.96e-05	0.000295	CcSEcCtD
Dasatinib—ABCB1—vagina—uterine cancer	5.96e-05	0.000344	CbGeAlD
Dasatinib—Gastrointestinal disorder—Epirubicin—uterine cancer	5.95e-05	0.000294	CcSEcCtD
Dasatinib—Fatigue—Epirubicin—uterine cancer	5.94e-05	0.000294	CcSEcCtD
Dasatinib—Pain—Epirubicin—uterine cancer	5.89e-05	0.000291	CcSEcCtD
Dasatinib—Constipation—Epirubicin—uterine cancer	5.89e-05	0.000291	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	5.81e-05	0.000287	CcSEcCtD
Dasatinib—Insomnia—Doxorubicin—uterine cancer	5.77e-05	0.000285	CcSEcCtD
Dasatinib—Dyspnoea—Doxorubicin—uterine cancer	5.68e-05	0.000281	CcSEcCtD
Dasatinib—Feeling abnormal—Epirubicin—uterine cancer	5.68e-05	0.000281	CcSEcCtD
Dasatinib—Somnolence—Doxorubicin—uterine cancer	5.67e-05	0.00028	CcSEcCtD
Dasatinib—Gastrointestinal pain—Epirubicin—uterine cancer	5.64e-05	0.000279	CcSEcCtD
Dasatinib—Dyspepsia—Doxorubicin—uterine cancer	5.61e-05	0.000278	CcSEcCtD
Dasatinib—Decreased appetite—Doxorubicin—uterine cancer	5.54e-05	0.000274	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Doxorubicin—uterine cancer	5.5e-05	0.000272	CcSEcCtD
Dasatinib—Fatigue—Doxorubicin—uterine cancer	5.5e-05	0.000272	CcSEcCtD
Dasatinib—Urticaria—Epirubicin—uterine cancer	5.47e-05	0.000271	CcSEcCtD
Dasatinib—Pain—Doxorubicin—uterine cancer	5.45e-05	0.00027	CcSEcCtD
Dasatinib—Constipation—Doxorubicin—uterine cancer	5.45e-05	0.00027	CcSEcCtD
Dasatinib—Body temperature increased—Epirubicin—uterine cancer	5.45e-05	0.000269	CcSEcCtD
Dasatinib—Abdominal pain—Epirubicin—uterine cancer	5.45e-05	0.000269	CcSEcCtD
Dasatinib—Feeling abnormal—Doxorubicin—uterine cancer	5.25e-05	0.00026	CcSEcCtD
Dasatinib—Gastrointestinal pain—Doxorubicin—uterine cancer	5.21e-05	0.000258	CcSEcCtD
Dasatinib—Hypersensitivity—Epirubicin—uterine cancer	5.08e-05	0.000251	CcSEcCtD
Dasatinib—Urticaria—Doxorubicin—uterine cancer	5.07e-05	0.00025	CcSEcCtD
Dasatinib—Abdominal pain—Doxorubicin—uterine cancer	5.04e-05	0.000249	CcSEcCtD
Dasatinib—Body temperature increased—Doxorubicin—uterine cancer	5.04e-05	0.000249	CcSEcCtD
Dasatinib—Asthenia—Epirubicin—uterine cancer	4.94e-05	0.000244	CcSEcCtD
Dasatinib—Pruritus—Epirubicin—uterine cancer	4.88e-05	0.000241	CcSEcCtD
Dasatinib—Diarrhoea—Epirubicin—uterine cancer	4.72e-05	0.000233	CcSEcCtD
Dasatinib—Hypersensitivity—Doxorubicin—uterine cancer	4.7e-05	0.000232	CcSEcCtD
Dasatinib—Asthenia—Doxorubicin—uterine cancer	4.57e-05	0.000226	CcSEcCtD
Dasatinib—Dizziness—Epirubicin—uterine cancer	4.56e-05	0.000225	CcSEcCtD
Dasatinib—Pruritus—Doxorubicin—uterine cancer	4.51e-05	0.000223	CcSEcCtD
Dasatinib—Vomiting—Epirubicin—uterine cancer	4.38e-05	0.000217	CcSEcCtD
Dasatinib—Diarrhoea—Doxorubicin—uterine cancer	4.36e-05	0.000216	CcSEcCtD
Dasatinib—Rash—Epirubicin—uterine cancer	4.35e-05	0.000215	CcSEcCtD
Dasatinib—Dermatitis—Epirubicin—uterine cancer	4.34e-05	0.000215	CcSEcCtD
Dasatinib—Headache—Epirubicin—uterine cancer	4.32e-05	0.000213	CcSEcCtD
Dasatinib—Dizziness—Doxorubicin—uterine cancer	4.22e-05	0.000208	CcSEcCtD
Dasatinib—Nausea—Epirubicin—uterine cancer	4.09e-05	0.000202	CcSEcCtD
Dasatinib—Vomiting—Doxorubicin—uterine cancer	4.05e-05	0.0002	CcSEcCtD
Dasatinib—Rash—Doxorubicin—uterine cancer	4.02e-05	0.000199	CcSEcCtD
Dasatinib—Dermatitis—Doxorubicin—uterine cancer	4.02e-05	0.000199	CcSEcCtD
Dasatinib—Headache—Doxorubicin—uterine cancer	3.99e-05	0.000197	CcSEcCtD
Dasatinib—ABCB1—lymph node—uterine cancer	3.85e-05	0.000223	CbGeAlD
Dasatinib—Nausea—Doxorubicin—uterine cancer	3.79e-05	0.000187	CcSEcCtD
Dasatinib—RIPK2—Signaling Pathways—TP53—uterine cancer	2.51e-06	1.07e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—uterine cancer	2.51e-06	1.07e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—uterine cancer	2.49e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—ERBB2—uterine cancer	2.49e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTEN—uterine cancer	2.49e-06	1.06e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—uterine cancer	2.48e-06	1.06e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—CTNNB1—uterine cancer	2.47e-06	1.05e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ESR1—uterine cancer	2.46e-06	1.05e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—MTHFR—uterine cancer	2.45e-06	1.05e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—ERBB2—uterine cancer	2.45e-06	1.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CCL2—uterine cancer	2.45e-06	1.04e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—CTNNB1—uterine cancer	2.45e-06	1.04e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—uterine cancer	2.43e-06	1.04e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EP300—uterine cancer	2.43e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PIK3CA—uterine cancer	2.43e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL8—uterine cancer	2.41e-06	1.03e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PTEN—uterine cancer	2.41e-06	1.03e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—uterine cancer	2.4e-06	1.02e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—uterine cancer	2.4e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—uterine cancer	2.39e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—CDKN1B—uterine cancer	2.39e-06	1.02e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—RRM2—uterine cancer	2.39e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—PTEN—uterine cancer	2.38e-06	1.02e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—uterine cancer	2.38e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—PIK3CA—uterine cancer	2.38e-06	1.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—PIK3CA—uterine cancer	2.37e-06	1.01e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—uterine cancer	2.37e-06	1.01e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—EP300—uterine cancer	2.37e-06	1.01e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—PIK3CA—uterine cancer	2.37e-06	1.01e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL8—uterine cancer	2.36e-06	1.01e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—ERBB2—uterine cancer	2.36e-06	1.01e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—uterine cancer	2.36e-06	1.01e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—uterine cancer	2.36e-06	1.01e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CDKN1B—uterine cancer	2.36e-06	1e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—ERBB2—uterine cancer	2.33e-06	9.93e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL8—uterine cancer	2.33e-06	9.91e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—DCN—uterine cancer	2.32e-06	9.88e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—PIK3CA—uterine cancer	2.32e-06	9.88e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PIK3CA—uterine cancer	2.31e-06	9.83e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CDKN1B—uterine cancer	2.31e-06	9.83e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—uterine cancer	2.3e-06	9.79e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—uterine cancer	2.3e-06	9.79e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EP300—uterine cancer	2.3e-06	9.79e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—uterine cancer	2.29e-06	9.77e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—uterine cancer	2.29e-06	9.76e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—uterine cancer	2.28e-06	9.72e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EP300—uterine cancer	2.27e-06	9.69e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CDKN1B—uterine cancer	2.27e-06	9.68e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—uterine cancer	2.27e-06	9.67e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—uterine cancer	2.27e-06	9.66e-06	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—uterine cancer	2.27e-06	9.65e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—CTNNB1—uterine cancer	2.26e-06	9.62e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—uterine cancer	2.24e-06	9.56e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—uterine cancer	2.24e-06	9.54e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CTNNB1—uterine cancer	2.23e-06	9.49e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—uterine cancer	2.22e-06	9.45e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—uterine cancer	2.22e-06	9.45e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—uterine cancer	2.21e-06	9.44e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—uterine cancer	2.21e-06	9.42e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—uterine cancer	2.2e-06	9.38e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—uterine cancer	2.2e-06	9.36e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—uterine cancer	2.2e-06	9.36e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—uterine cancer	2.2e-06	9.36e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—uterine cancer	2.19e-06	9.33e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—uterine cancer	2.19e-06	9.32e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CDKN1B—uterine cancer	2.19e-06	9.32e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—uterine cancer	2.19e-06	9.31e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.18e-06	9.31e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—uterine cancer	2.18e-06	9.29e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CTNNB1—uterine cancer	2.18e-06	9.29e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—uterine cancer	2.18e-06	9.27e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—uterine cancer	2.17e-06	9.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—uterine cancer	2.17e-06	9.24e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCL2—uterine cancer	2.17e-06	9.24e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	2.16e-06	9.22e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CDKN1B—uterine cancer	2.16e-06	9.2e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—uterine cancer	2.15e-06	9.16e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—uterine cancer	2.15e-06	9.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CTNNB1—uterine cancer	2.15e-06	9.14e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—uterine cancer	2.14e-06	9.14e-06	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—uterine cancer	2.14e-06	9.1e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—uterine cancer	2.13e-06	9.09e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—uterine cancer	2.13e-06	9.06e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—uterine cancer	2.12e-06	9.05e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—uterine cancer	2.12e-06	9.04e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—uterine cancer	2.12e-06	9.03e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—EP300—uterine cancer	2.11e-06	9.01e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—uterine cancer	2.11e-06	9e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—uterine cancer	2.11e-06	8.98e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EP300—uterine cancer	2.1e-06	8.94e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—uterine cancer	2.09e-06	8.92e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—uterine cancer	2.09e-06	8.91e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—STK11—uterine cancer	2.08e-06	8.87e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CYP19A1—uterine cancer	2.08e-06	8.87e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EP300—uterine cancer	2.07e-06	8.82e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—uterine cancer	2.07e-06	8.81e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CTNNB1—uterine cancer	2.07e-06	8.8e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.06e-06	8.79e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—uterine cancer	2.04e-06	8.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CTNNB1—uterine cancer	2.04e-06	8.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—uterine cancer	2.03e-06	8.66e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EP300—uterine cancer	2.03e-06	8.63e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—uterine cancer	2.02e-06	8.62e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—uterine cancer	2.02e-06	8.6e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—uterine cancer	2.01e-06	8.58e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—uterine cancer	2.01e-06	8.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—uterine cancer	2.01e-06	8.55e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—uterine cancer	2e-06	8.53e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EP300—uterine cancer	1.99e-06	8.5e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—uterine cancer	1.99e-06	8.47e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—uterine cancer	1.98e-06	8.45e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—uterine cancer	1.96e-06	8.37e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—uterine cancer	1.96e-06	8.35e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—uterine cancer	1.96e-06	8.35e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	1.95e-06	8.33e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—uterine cancer	1.95e-06	8.32e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—uterine cancer	1.95e-06	8.31e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—uterine cancer	1.94e-06	8.28e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—uterine cancer	1.94e-06	8.27e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—uterine cancer	1.94e-06	8.26e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—uterine cancer	1.94e-06	8.25e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—uterine cancer	1.94e-06	8.25e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—uterine cancer	1.93e-06	8.24e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—EP300—uterine cancer	1.92e-06	8.2e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EP300—uterine cancer	1.92e-06	8.18e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—uterine cancer	1.92e-06	8.18e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—uterine cancer	1.91e-06	8.14e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—uterine cancer	1.9e-06	8.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EP300—uterine cancer	1.9e-06	8.08e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—uterine cancer	1.89e-06	8.08e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—uterine cancer	1.89e-06	8.07e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CDKN1B—uterine cancer	1.89e-06	8.06e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—uterine cancer	1.89e-06	8.05e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—uterine cancer	1.88e-06	8.03e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—uterine cancer	1.87e-06	7.97e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—uterine cancer	1.87e-06	7.95e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	1.86e-06	7.94e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—uterine cancer	1.86e-06	7.94e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—uterine cancer	1.86e-06	7.92e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—uterine cancer	1.85e-06	7.89e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—uterine cancer	1.85e-06	7.88e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—uterine cancer	1.83e-06	7.8e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—uterine cancer	1.82e-06	7.75e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—uterine cancer	1.81e-06	7.7e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—uterine cancer	1.8e-06	7.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—uterine cancer	1.8e-06	7.65e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—uterine cancer	1.79e-06	7.65e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—uterine cancer	1.79e-06	7.65e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CTNNB1—uterine cancer	1.79e-06	7.61e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—uterine cancer	1.79e-06	7.61e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—uterine cancer	1.78e-06	7.61e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—uterine cancer	1.77e-06	7.56e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—uterine cancer	1.77e-06	7.55e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—uterine cancer	1.76e-06	7.49e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—uterine cancer	1.75e-06	7.47e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—uterine cancer	1.74e-06	7.42e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—uterine cancer	1.74e-06	7.4e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—uterine cancer	1.72e-06	7.33e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—uterine cancer	1.71e-06	7.3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—uterine cancer	1.7e-06	7.24e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—uterine cancer	1.69e-06	7.2e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—uterine cancer	1.68e-06	7.17e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CDKN1B—uterine cancer	1.67e-06	7.13e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—uterine cancer	1.67e-06	7.1e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—uterine cancer	1.66e-06	7.08e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EP300—uterine cancer	1.66e-06	7.08e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—uterine cancer	1.64e-06	7e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—uterine cancer	1.64e-06	7e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—uterine cancer	1.64e-06	6.97e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—uterine cancer	1.63e-06	6.95e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—uterine cancer	1.62e-06	6.91e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—STK11—uterine cancer	1.61e-06	6.85e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.61e-06	6.85e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—uterine cancer	1.61e-06	6.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CTNNB1—uterine cancer	1.58e-06	6.74e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—uterine cancer	1.57e-06	6.7e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—uterine cancer	1.57e-06	6.7e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—uterine cancer	1.56e-06	6.67e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—uterine cancer	1.56e-06	6.66e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—uterine cancer	1.56e-06	6.63e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—uterine cancer	1.55e-06	6.62e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—uterine cancer	1.55e-06	6.62e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—uterine cancer	1.55e-06	6.61e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—uterine cancer	1.55e-06	6.59e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—uterine cancer	1.54e-06	6.57e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—uterine cancer	1.53e-06	6.52e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—uterine cancer	1.53e-06	6.5e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—uterine cancer	1.5e-06	6.39e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—uterine cancer	1.48e-06	6.31e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—uterine cancer	1.48e-06	6.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EP300—uterine cancer	1.47e-06	6.26e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—uterine cancer	1.47e-06	6.25e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—uterine cancer	1.45e-06	6.18e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—uterine cancer	1.45e-06	6.16e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—uterine cancer	1.44e-06	6.12e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—uterine cancer	1.43e-06	6.11e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—uterine cancer	1.43e-06	6.08e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—uterine cancer	1.42e-06	6.06e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—uterine cancer	1.42e-06	6.05e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—uterine cancer	1.42e-06	6.03e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—uterine cancer	1.4e-06	5.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—uterine cancer	1.39e-06	5.93e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—uterine cancer	1.39e-06	5.91e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—uterine cancer	1.39e-06	5.91e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.38e-06	5.88e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—EP300—uterine cancer	1.38e-06	5.87e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—uterine cancer	1.38e-06	5.86e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—uterine cancer	1.37e-06	5.86e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—uterine cancer	1.37e-06	5.85e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—uterine cancer	1.37e-06	5.82e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—uterine cancer	1.36e-06	5.82e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—uterine cancer	1.36e-06	5.78e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—uterine cancer	1.34e-06	5.7e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—uterine cancer	1.31e-06	5.6e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—EP300—uterine cancer	1.3e-06	5.55e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—uterine cancer	1.3e-06	5.53e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—uterine cancer	1.28e-06	5.44e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—uterine cancer	1.27e-06	5.41e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—uterine cancer	1.25e-06	5.33e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—uterine cancer	1.23e-06	5.23e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—uterine cancer	1.22e-06	5.22e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—uterine cancer	1.21e-06	5.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—uterine cancer	1.21e-06	5.14e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—uterine cancer	1.19e-06	5.06e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—uterine cancer	1.18e-06	5.04e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—uterine cancer	1.16e-06	4.95e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—uterine cancer	1.16e-06	4.94e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—uterine cancer	1.15e-06	4.88e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—uterine cancer	1.14e-06	4.84e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—uterine cancer	1.09e-06	4.65e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—uterine cancer	1.09e-06	4.63e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—uterine cancer	1.05e-06	4.48e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—EP300—uterine cancer	1.04e-06	4.43e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—uterine cancer	1.02e-06	4.34e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—uterine cancer	1.01e-06	4.29e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—uterine cancer	1e-06	4.28e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—uterine cancer	9.63e-07	4.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—uterine cancer	8.88e-07	3.79e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—uterine cancer	8.71e-07	3.71e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—uterine cancer	8.33e-07	3.55e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—EP300—uterine cancer	8.3e-07	3.54e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—uterine cancer	7.87e-07	3.35e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—uterine cancer	7.69e-07	3.28e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—uterine cancer	6.72e-07	2.86e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—EP300—uterine cancer	6.41e-07	2.73e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—uterine cancer	6.28e-07	2.68e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—uterine cancer	6.14e-07	2.62e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—uterine cancer	5.02e-07	2.14e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—uterine cancer	4.74e-07	2.02e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—uterine cancer	3.87e-07	1.65e-06	CbGpPWpGaD
